Diagnosis is based on identification of at least 20% myeloblasts in the bone marrow (BM) or peripheral blood (PB) according to 2016 World Health Organization (WHO) guidelines, except for AML with specific cytogenetic abnormalities or nucleophosmin 1 (NPM1) mutated leukemias (Giudice V et, 2021; Heuser M et al., 2020; Khoury JD et al., 2022). This evidence concerns the gene NPM1 and acute myeloid leukemia.